How Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Expected To Grow At 4.6% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Be Worth By 2029?
Over the past few years, the market size of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer has seen consistent growth. Projected to increase from $1.25 billion in 2024 to $1.31 billion in 2025, it is expected to register a compound annual growth rate (CAGR) of 4.8%. The historical growth of this market is primarily due to the escalating use of companion diagnostics, heightened awareness of HER2 biomarkers amongst oncologists, an intensified focus on bespoke cancer treatments, burgeoning interest in antibody-drug conjugates, and the expansion of reimbursement for targeted therapies.
The market size for the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is anticipated to experience consistent growth over the coming years, expanding to $1.57 billion in 2029 with a compound annual growth rate (CAGR) of 4.6%. The expected growth in this projected period has been linked to the ongoing rise in accessible molecular diagnostic labs, growing promotional campaigns for the screening of gastric cancer, increased utilization of next-generation sequencing (NGS), escalating demand for outpatient oncology care services, and an upswing in international regulatory endorsements for HER2 medications. During the predicted period, the prominent trends include improvement in treatment sequences, the implementation of nanotechnology within drug administration, the use of artificial intelligence in HER2 diagnostics, progress in antibody-dependent cellular cytotoxicity, and developments in therapeutic blends of immunotherapy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp
What External And Internal Drivers Are Influencing The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The increase in the use of personalized cancer treatment is predicted to boost the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in the future. Personalized medicine, or targeted therapy, employs specific medications or substances to stop cancer growth by concentrating on distinct molecules that are part of tumour development. The enhanced use of targeted therapy is driven largely by groundbreaking advances in genetic profiling, making treatments more accurate according to the specific characteristics of an individual’s tumour. This leads to increased effectiveness and reduced side effects. In the case of HER2-positive gastric cancer, targeted therapy works by directly targeting the HER2 protein, which is highly expressed in these cancers, thereby slowing down the progression of the disease and enhancing patient outcomes. For example, in February 2024, as reported by the Personalized Medicine Coalition, a professional association based in the US, the Food and Drug Administration (FDA) granted approval for 16 new personalized medications, namely 7 for cancer and 3 for various other diseases and conditions in the year 2023. This marked an increase from just 6 such approvals in 2022. As a result, the growing utilization of targeted cancer treatment is leading to an upward growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
What Segmentation Insights Are Provided In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Research?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
Which Notable Trends Are Transforming The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Outlook?
Leaders in the field of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer are working diligently to receive authorizations for cutting-edge treatments, such as high-level immunotherapy supplement combination regimens, which involves combining immune checkpoint suppressors with targeted treatments and chemotherapy. This approach provides improved patient results in initial treatment scenarios. This methodology does its job by utilizing the human body’s immune system to hamper programmed death (PD)-1 or programmed death (PD)-L1 interaction while simultaneously engaging HER2 receptors, and employing chemotherapy, thus strengthening anti-cancer activity and improving survival percentages. For example, in March 2025, the U.S. Food and Drug Administration (FDA) granted approval to Merck & Co., Inc., an American biopharmaceutical establishment, for Keytruda (pembrolizumab), paired with trastuzumab and chemotherapy, as an initial treatment for adult patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with tumors that express programmed death (PD)-L1. This more recently authorized combined treatment showed a significant advantage in the median delay to disease progression and the overall survival rates versus traditional regimens. Displaying an overall response rate of 73% and a more extended average response duration, this treatment marks a transformative shift in handling advanced HER2-positive gastric cancers.
Who Are The Leading Companies Driving The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25787&type=smp
Browse Through More Reports Similar to the Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market 2025, By The Business Research Company
Gastric Ulcers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report
Gastrointestinal Stromal Tumor Global Market Report 2025
Esophageal Cancer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
